IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Independent Advisor Alliance

Independent Advisor Alliance increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 49.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,729 shares of the medical research company’s stock after acquiring an additional 574 shares during the quarter. Independent Advisor Alliance’s holdings in IQVIA were worth $340,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Smith Group Asset Management LLC purchased a new position in IQVIA in the 4th quarter valued at $1,616,000. Nordea Investment Management AB grew its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. purchased a new position in IQVIA in the 4th quarter valued at $941,000. Fifth Third Bancorp grew its position in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS grew its position in IQVIA by 22.0% in the 4th quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after buying an additional 2,700 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Up 1.9 %

Shares of IQV stock opened at $188.45 on Wednesday. The firm has a 50-day moving average price of $196.06 and a 200 day moving average price of $209.52. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.34. The company has a market capitalization of $33.23 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IQV. Truist Financial reiterated a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. BTIG Research lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Barclays decreased their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. UBS Group decreased their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Robert W. Baird decreased their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.